Clinical trials, medication approvals, new research and care-access changes—translated into useful context. See exactly what is established, what is still experimental and what needs more study.
Use the condition filter below for autism, ADHD, OCD, mood, sleep or schizophrenia and psychosis. A research headline is different from everyday support.
Search by condition or treatment, then refine by topic and evidence or regulatory status.
30 of 30 updates
Regulatory status is separate from research strength: FDA approval does not guarantee superiority, and an early trial is not authorization to use a treatment.
Bipolar disorder · Long-acting medication
Evidence update
Long-acting aripiprazole linked to fewer hospital visits in bipolar disorder—but risks matter
In a matched real-world study, people switching to injections had lower adjusted all-cause hospitalization (HR 0.77) and emergency-visit hazards (HR 0.88) than those continuing pills. Obesity and extrapyramidal symptoms were more frequent.
What evidence is available?
Peer-reviewed observational target-trial emulation; 1,814 matched patients per group
Regulatory or policy status
Specific formulations approved for adult bipolar I maintenance; observational study, not a new approval
Why this matters · What it does not prove
Why this matters
An existing adult bipolar I maintenance option warrants informed comparison of treatment burden, benefits, metabolic health and movement symptoms.
Important limits and safety
No randomized assignment or causal proof, and all-cause hospitalization is not a direct measure of bipolar relapse. No changes to medicine without a psychiatrist.
Ultrasound may influence delusion ratings, but this pilot studied only ten people
One ten-minute MRI-guided ultrasound session produced a preliminary difference in overall delusion ratings versus sham (p = 0.002). Hallucination ratings did not significantly improve. The exploratory seven-day comparison did not remain significant after correction.
What evidence is available?
Peer-reviewed randomized sham-controlled crossover pilot, ten participants
Regulatory or policy status
Experimental for psychosis, not an FDA-authorized psychiatric treatment
Why this matters · What it does not prove
Why this matters
Precise noninvasive targeting of deep circuits could be useful in future psychosis research and better trial designs.
Important limits and safety
Ten people and seven-day follow-up cannot establish durable benefit, meaningful everyday improvement or longer-term safety. Continue established care.
Autism trial will use an EEG signature to select participants—but benefit is unproven
Spinogenix announced an autism cohort for the CLARITY codabakalner study. A sponsor-supported preprint identified an elevated gamma EEG pattern in 35 of 159 autistic participants (22%), but this has not been peer reviewed and does not demonstrate a drug response. The registry updated October 9 listed the study as not yet recruiting.
What evidence is available?
Planned Phase 2b autism trial; EEG subgroup data from a non-peer-reviewed preprint
Regulatory or policy status
Codabakalner (SPG601) is investigational, not FDA-approved for autism
Why this matters · What it does not prove
Why this matters
Biomarker-selected enrollment may let researchers test whether a treatment works in a biologically defined subgroup, rather than assuming all autistic participants share the same target. Future controlled results—not screening EEG findings—must demonstrate meaningful benefit.
Important limits and safety
The 22% result is sample-specific and comes from a preprint with sponsor involvement. A small previous trial studied adults with fragile X, not efficacy in idiopathic autism. An EEG is not a validated clinical treatment-selection test, Fast Track designation for fragile X is not approval, and families should not change care or obtain EEG testing because of this announcement.
mRNA for schizophrenia? GRIA3 study points to a possible future genetic subgroup treatment
An October 12 Biological Psychiatry study linked a rare GRIA3 variant in one family to protein loss, restored expression in laboratory neurons, and tested a GRIA3 mRNA candidate in a drug-induced mouse psychosis model. No patients received the candidate and no human benefit was shown.
What evidence is available?
Peer-reviewed preclinical paper: human-derived neurons and mouse model, no human efficacy trial
Regulatory or policy status
Experimental GRIA3 mRNA candidate; no approved schizophrenia treatment
Why this matters · What it does not prove
Why this matters
The research illustrates a route from rare human genetics to a molecular intervention—an important proof of concept for precision psychiatry, but not an available therapy.
Important limits and safety
Mouse behavior cannot establish effectiveness for human schizophrenia. The mutation is rare, brain delivery and long-term safety remain unanswered, and there is no clinical trial or treatment authorization. Evidence-based schizophrenia and psychosis care should continue.
Children, caffeine and sleep: study finds small brain-imaging associations, not proof of damage
An October 15 publication analyzed caffeinated drinks, caregiver-reported sleep and MRI measures in 9,632 children ages 9–11. Higher caffeine intake—mostly soft drinks—was associated with shorter sleep and small differences in cortical surface area, with some links to later self-reported attention and mood symptoms.
What evidence is available?
Peer-reviewed observational study of 9,632 children ages 9–11
Regulatory or policy status
Association, not evidence of a new treatment or causal harm
Why this matters · What it does not prove
Why this matters
Parents and clinicians can use the findings as a prompt to ask about beverage habits and sleep in children with attention or mood concerns, without treating MRI associations as a diagnosis or individual prediction.
Important limits and safety
The study was observational and relied on drink and sleep reports. Effects were small; sugar, diet and other factors may contribute. It did not show that a weekly drink damages a child's brain or that reducing caffeine treats ADHD, anxiety or depression.
FDA schedules November 10 focused-ultrasound research workshop for neurological and psychiatric applications
FDA and the Focused Ultrasound Foundation are hosting a free hybrid public workshop November 10, 2026, 9 a.m.–5 p.m. Eastern, at Hilton McLean Tysons Corner, Virginia, and by webcast. The preliminary agenda covers psychiatric neuromodulation evidence, patient risks, clinical trial design, nonclinical safety and blood-brain barrier opening. Both virtual and in-person registration close November 5 at 4 p.m. ET.
What evidence is available?
Official FDA workshop announcement; not a clinical outcome trial
Regulatory or policy status
Regulatory science discussion; no new psychiatric authorization
Why this matters · What it does not prove
Why this matters
More consistent safety standards and stronger outcome measures may improve future trials of targeted neurotechnology. It is an opportunity to follow regulatory expectations, not a newly available treatment.
Important limits and safety
Co-sponsoring a workshop is not FDA clearance, approval, or endorsement of ultrasound for depression, OCD, autism, ADHD, schizophrenia or other psychiatric indications. Intensity, targeting and purpose vary by technology; early research should not replace established care.
GLP-1 diabetes medicines linked to fewer psychiatric hospital and emergency visits—not causal proof
A Lancet Psychiatry cohort found that among adults with schizophrenia and type 2 diabetes, starting GLP-1 receptor agonist-based therapy was associated with lower adjusted hazards of psychiatric hospitalization (HR 0.76) and emergency department presentation (HR 0.71) than non-initiation. Researchers also compared other diabetes drug classes. These reflect 24% and 29% lower relative hazards, not reductions in an individual's absolute risk.
What evidence is available?
Peer-reviewed observational EHR cohort; 70,257 adults with schizophrenia and type 2 diabetes
Regulatory or policy status
GLP-1 medicines are not FDA-approved treatments for schizophrenia
Why this matters · What it does not prove
Why this matters
Integrated metabolic and psychiatric care could be important when antipsychotic treatment and diabetes or other cardiometabolic issues overlap. The association deserves randomized confirmation and better study of clinical symptoms and everyday function.
Important limits and safety
This was observational research and included people with type 2 diabetes; it cannot establish that GLP-1 medications prevent psychosis or treat schizophrenia, or be generalized to people without diabetes. No medication should be started, stopped or changed for psychiatric purposes based on these findings.
Single-day bipolar-depression TMS study highlighted again: promising rates, no control group
The ONE-BD paper was published online August 19 and highlighted in an October 15 announcement. In a 30-person bipolar I depression case series combining one-day accelerated theta-burst stimulation with D-cycloserine, 73.3% met response and 43.3% met remission criteria at six weeks; no mania switches were observed in this small cohort. The study was not randomized or sham controlled.
What evidence is available?
Published open-label, uncontrolled case series (30 adults); originally published August 19, 2026
Regulatory or policy status
The studied single-day TMS plus D-cycloserine protocol is experimental
Why this matters · What it does not prove
Why this matters
If replicated in controlled trials, shorter stimulation regimens could potentially reduce treatment visits and travel burden. The results provide a research question, not an established therapeutic option.
Important limits and safety
Without a comparison group, these numbers cannot establish that the protocol caused improvement. Thirty people cannot rule out uncommon adverse effects or mood switching. The particular combination protocol is not an established FDA-cleared treatment for bipolar depression; medical supervision is essential.
36 high-confidence genes linked to OCD and chronic tic disorders: what families should know
A September 1 Nature Neuroscience study, highlighted by UCSF on October 14, analyzed rare protein-damaging variants among 3,964 people with OCD, chronic tic disorders (including Tourette syndrome), or both. The team identified 36 high-confidence risk genes across analyses and found biological overlap with other neurodevelopmental conditions.
Genetic risk discovery; no approved diagnostic panel or treatment
Why this matters · What it does not prove
Why this matters
The discovery adds credible clues about shared molecular pathways and could eventually help researchers identify and test targeted approaches. The clinical priority today remains accurate assessment, ERP for OCD, CBIT for impairing tics, and appropriate treatment of co-occurring needs.
Important limits and safety
Statistical gene associations do not predict an individual's diagnosis, establish one universal cause, justify routine genetic screening, or create any gene-targeted therapy. The original paper was published September 1, not October 14.
VQW-765 social anxiety Phase 3 trial fails to outperform placebo; program paused
Vanda reported that its 546-participant Study 3201 did not meet its prespecified primary outcome during a standardized speaking challenge: average distress scores among female participants were 65.6 with VQW-765 and 66.0 with placebo (p=0.8899). The secondary outcome in all participants also missed its target. Development is on hold pending analysis.
Experimental VQW-765 program paused after missed primary and key secondary endpoints
Why this matters · What it does not prove
Why this matters
Well-conducted negative trials are useful evidence: larger confirmatory testing can contradict promising early signals. NeuroCoach reports unsuccessful trials rather than showcasing positive announcements alone.
Important limits and safety
These company-reported findings do not establish that VQW-765 is effective for social anxiety. Full independent analysis is pending. The program pause is not evidence that the medicine is unsafe; Vanda described it as generally well tolerated. Evidence-based treatment remains available.
Depression DBS study links targeted brain pathways to sustained response—but does not prove efficacy
A paper published October 1 and highlighted October 13 analyzed stimulation connectivity and symptom outcomes from 131 adults with treatment-resistant depression who had received subcallosal cingulate deep brain stimulation. Responders' stimulation more consistently reached selected white-matter pathways, including the left cingulum bundle and medial uncinate fasciculus.
What evidence is available?
Peer-reviewed retrospective analysis of 131 DBS recipients from three cohorts
Regulatory or policy status
DBS for depression remains investigational; not a new FDA authorization
Why this matters · What it does not prove
Why this matters
Mapping individual brain pathways might help researchers improve DBS targeting and design stronger future clinical trials. TMS and surgically implanted DBS have very different risks and established uses.
Important limits and safety
Retrospective associations across people already treated cannot show DBS is effective versus usual care, establish which patients benefit or prove connectivity-guided surgery is superior. DBS for depression remains investigational and carries procedural risks.
Hansoh Pharma reported 42-day results from 363 adults randomized to three dose ranges of obuprazine (HS-10380 / TRTL-107), an aripiprazole reference group or placebo. All three obuprazine doses had greater average PANSS symptom improvements than placebo; reported placebo-adjusted differences were −16.7, −13.2 and −14.7 points across dose ranges. Details were presented at ECNP 2026; a full peer-reviewed publication is pending.
What evidence is available?
Randomized Phase 2b study (363 adults); October 10 poster and October 12 company report; peer review pending
Regulatory or policy status
Investigational antipsychotic; not FDA-approved
Why this matters · What it does not prove
Why this matters
The findings justify following this experimental antipsychotic's development, including whether it improves functioning and important negative symptoms over time. Families can use the explainer to distinguish an encouraging trial result from an available treatment.
Important limits and safety
The 42-day sponsor-reported results do not establish long-term safety, comparative superiority to approved antipsychotics, improvement in real-world cognition, or FDA approval. No changes to prescribed medicines should be based on this announcement.
Could ACE levels help identify treatment-resistant psychosis? Early evidence, not a blood test
A Johns Hopkins announcement on October 12 highlighted a JAMA Psychiatry study published September 9. Researchers measured angiotensin-converting enzyme (ACE) in 78 controls and 122 people with early-stage psychosis, including 31 classified as treatment resistant. Lower blood ACE protein levels were associated with treatment resistance, but the study did not establish diagnostic accuracy.
Exploratory biomarker; not an approved or validated test
Why this matters · What it does not prove
Why this matters
With independent validation, biological markers could one day complement clinical assessment to identify people who may benefit from a different treatment plan sooner. For now, care decisions must use established specialist assessment.
Important limits and safety
Small cross-sectional subgroups cannot show that ACE causes psychosis or predict whether a particular person will respond to treatment. No ACE blood test is recommended to diagnose or monitor treatment resistance. Do not stop or change ACE inhibitor blood-pressure medication or psychiatric treatment because of this result.
MECP2 regulatory variants offer an early clue to some autism presentations
Researchers reported rare DNA changes that alter control of the X-linked MECP2 gene in some autistic males. One variant reduced MECP2 expression by about 30% in laboratory-grown human neurons; related mouse findings offer biological context. The study cannot explain autism diagnoses overall or the full sex difference in diagnosis rates.
What evidence is available?
Peer-reviewed laboratory and genetic research
Regulatory or policy status
Research discovery; not a screening or treatment recommendation
Why this matters · What it does not prove
Why this matters
Noncoding genetic variants are difficult to interpret. Studying their biological effects may eventually improve understanding of specific neurodevelopmental pathways and rare variants.
Important limits and safety
This is not a clinical genetic screening recommendation, proof of autism causation in every case, or a route to a treatment. Laboratory and animal results should not be treated as predictions about an individual. Families considering genetic evaluation should discuss current indications with a qualified clinician or genetic counselor.
England review calls for needs-led support alongside diagnosis
The independent review chaired by Professor Peter Fonagy recommends earlier needs-led support while awaiting assessment, integrated attention to co-occurring problems and outcomes focused on participation. These recommendations concern England, not new US entitlements.
What evidence is available?
Policy review, not a trial
Regulatory or policy status
England: proposed reforms
Why this matters · What it does not prove
Why this matters
People may need support with school, work, relationships and daily functioning long before assessment. Document functional needs and explore local support while preserving access to diagnosis.
Important limits and safety
This is a government-commissioned policy review, not a clinical trial or an implemented reform. It neither dismisses the importance of diagnosis nor establishes widespread overdiagnosis or changes US laws.
FDA approves WELTRUZA, a monthly injectable olanzapine—with monitoring still essential
FDA approved a once-monthly, clinician-administered subcutaneous olanzapine injection for adults with schizophrenia. It does not require routine post-injection observation, loading doses or ongoing oral supplementation; prior oral tolerability must be established if unknown. The Phase 3 SOLARIS study assessed symptoms and functioning.
What evidence is available?
FDA NDA 219007 and Phase 3 SOLARIS efficacy study
Regulatory or policy status
FDA approved October 8, 2026 for adults with schizophrenia
Why this matters · What it does not prove
Why this matters
An additional long-acting option may be worth discussing for people for whom daily medication is difficult, alongside preferences, metabolic monitoring, costs and access.
Important limits and safety
Olanzapine still carries significant metabolic, movement and sedation risks and a boxed warning for increased mortality in older adults with dementia-related psychosis. It is unknown whether post-injection delirium/sedation syndrome (seen with an older injected formulation) can occur with WELTRUZA; FDA requested enhanced safety reporting for five years. Do not change medication without a prescriber.
Eye-imaging differences in a small OCD study—not a diagnostic test
A peer-reviewed case–control study compared 29 people with OCD who had not taken psychiatric medication with 28 matched controls. Corneal confocal microscopy found more dendritic immune cells and lower nerve-fiber density, length and branching in the OCD group. These group-level differences were not significantly associated with overall OCD symptom severity. Evidence: preliminary observational biomarker research.
What evidence is available?
Small observational study
Regulatory or policy status
Preliminary; not a diagnostic test
Why this matters · What it does not prove
Why this matters
The findings offer one avenue for studying possible neuroimmune changes in OCD. Researchers could investigate whether such measures prove reliable in larger, more diverse and longitudinal samples. This does not change established clinical assessment or treatments such as exposure and response prevention (ERP).
Important limits and safety
A 57-person observational study cannot establish cause, diagnostic accuracy or whether eye imaging would improve outcomes. An eye scan is not an established OCD diagnostic or monitoring test, and these findings are not a reason to seek imaging or alter treatment.
FDA clinical hold continues for investigational evenamide
Newron reports a continuing FDA hold at US sites in its schizophrenia program. FDA feedback noted four deaths in evenamide-exposed trial participants versus one in placebo recipients and a possible cardiac safety signal; drug causality has not been established.
What evidence is available?
Investigational Phase 3; safety signal unresolved
Regulatory or policy status
US trial sites: FDA clinical hold
Why this matters · What it does not prove
Why this matters
People following treatment-resistant schizophrenia research deserve safety and regulatory context alongside any preliminary efficacy claims.
Important limits and safety
Evenamide is not FDA approved. Trial death counts do not establish cause or individual risk; research outside the US continues. Do not change existing treatment based on headlines.
ADHD and later cognitive impairment: what a large cohort study does—and does not—show
In a JAMA Psychiatry study of 187,341 adults aged 50 and older, 6.7% of participants with recorded ADHD and 3.4% without ADHD received a later diagnosis of mild cognitive impairment or dementia. Adjusted models found a higher hazard among those with ADHD, but the observational design cannot establish that ADHD causes cognitive decline.
Association only; no new screening or medication indication
Why this matters · What it does not prove
Why this matters
Adults and clinicians may benefit from distinguishing lifelong executive-function differences from meaningful changes over time and discussing concerns in the context of overall health and daily functioning.
Important limits and safety
The reported adjusted hazard ratio (4.60) is not an individual's probability of dementia, and the unadjusted percentages are not a personalized forecast. Diagnostic misclassification, differences in healthcare contact, reverse causation and other confounding remain possible. No evidence here shows that ADHD medications prevent or cause dementia; the study did not test treatment effects.
Online stepped-care PTSD trial: promising access, but higher dropout
In a randomized noninferiority trial of 84 adults with PTSD or subthreshold PTSD, a self-guided online program with criteria for stepping up to cognitive processing therapy (CPT) was compared with telehealth CPT. Both groups improved. Stepped care required about 8–10% less clinician time and met noninferiority criteria for clinician-rated PTSD symptoms just after treatment, but not for patient-reported PTSD symptoms or quality of life. Dropout was 43% with stepped care versus 26% with CPT. Evidence: randomized clinical trial with mixed outcomes.
What evidence is available?
Small randomized trial; mixed outcomes
Regulatory or policy status
Not a regulatory treatment approval
Why this matters · What it does not prove
Why this matters
Stepped-care models could help services reach more people by matching treatment intensity to needs. The results also highlight the importance of tracking symptoms, engagement, and whether someone needs to move to more intensive clinician-led therapy.
Important limits and safety
This study does not show that an unsupervised app can replace clinician-led trauma treatment, or that both approaches work equally well for everyone. The higher dropout rate and less favorable self-reported outcomes for stepped care matter. The sample was relatively small and predominantly female and White.
Sensory integration OT trial: specific daily-life gains, but broader results were mixed
In a 12-week randomized trial, 63 autistic preschoolers were assigned to usual educational support with or without about 36 hours of fidelity-checked Ayres Sensory Integration. Sixty completed the trial. Daily-living skills and individualized goals favored the ASI group; several broader measures were not significant.
What evidence is available?
Peer-reviewed randomized single-blind trial; 63 children randomized, 60 analyzed
Regulatory or policy status
Study evidence for specific functional goals; not an FDA autism treatment approval
Why this matters · What it does not prove
Why this matters
A trained occupational therapist may help some autistic preschoolers work toward meaningful, child-centered participation goals, such as routines, comfort or play.
Important limits and safety
One small, single-blind study from one setting with retrospective registration does not establish universal benefit or a change to autism itself. Results may not generalize to every age or type of sensory therapy. Individualized goals, preferences and measured outcomes matter.
FDA seeks public input on how to investigate ibogaine safely—not treatment approval
On October 5, 2026, FDA announced a request for information (Docket FDA-2026-N-10429) about designing closely monitored early-stage ibogaine trials. Initial federally supported research is prioritized for adults with opioid use disorder or PTSD. Public comments close November 20, 2026. The announcement did not approve ibogaine or establish clinical benefit.
What evidence is available?
FDA request for early-phase study-design input; no new efficacy evidence
Regulatory or policy status
Experimental; ibogaine not FDA approved
Why this matters · What it does not prove
Why this matters
This is a relevant change in the US research pathway for people exploring experimental PTSD treatments. It also offers a useful example of why research funding, protocol planning and drug approval are very different milestones.
Important limits and safety
FDA highlights life-threatening heart-rhythm abnormalities linked to QTc prolongation and possible neurological harm. Medication interactions, seizures and prolonged monitoring are serious concerns; do not use ibogaine or stop prescribed medicines outside qualified medical care. The request for comment is not evidence that it works.
FDA clears Motivista, a prescription digital therapeutic for negative symptoms of schizophrenia
The FDA granted 510(k) clearance in July 2026 for Motivista (CT-155), announced publicly October 5. The prescription smartphone-based treatment is indicated as an adjunct to clinician-managed outpatient care, including antipsychotic treatment, for adults 18 and older with stable positive symptoms. In the 457-person randomized CONVOKE trial, negative symptoms improved more with CT-155 than with a control app after 16 weeks (CAINS-MAP adjusted difference −2.6 points). Evidence: FDA-cleared for this specific use; supported by a randomized trial.
What evidence is available?
Randomized clinical trial
Regulatory or policy status
FDA cleared for a specified adult use
Why this matters · What it does not prove
Why this matters
Reduced motivation, pleasure and social engagement can substantially limit work, independence and relationships. This is a new clinician-supervised treatment option specifically directed at these negative symptoms.
Important limits and safety
FDA clearance is not proof of benefit for all patients or evidence that this treats hallucinations, delusions or acute psychosis. It complements—not replaces—antipsychotic and professional care. Real-world access, long-term outcomes and individual suitability should be checked with a clinician.
Ecopipam: new Tourette analyses while FDA review continues
Teva reported additional October 2026 analyses of its investigational dopamine D1 antagonist ecopipam for pediatric Tourette syndrome. In a post hoc pooled analysis, roughly 70% had a clinically meaningful tic reduction within eight weeks; an interim uncontrolled extension analysis reported a mean tic-severity reduction of 45.6% at 18 months. FDA Priority Review is underway, with a targeted decision in late Q1 2027. Evidence: promising later-stage studies; investigational, not approved.
What evidence is available?
Randomized Phase 3 plus exploratory analyses
Regulatory or policy status
Investigational; FDA Priority Review ongoing
Why this matters · What it does not prove
Why this matters
A different medication mechanism could eventually widen options for families navigating persistent tics, particularly where tolerability or response to existing approaches is difficult.
Important limits and safety
The newly reported response and extension figures are post hoc or uncontrolled analyses, not proof that 70% of all patients will benefit or that long-term treatment is effective and safe. Ecopipam is not FDA-approved as of this update. Review possible adverse effects and evidence-based CBIT with a qualified clinician.
Randomized autism tACS trial is intriguing—and still exploratory
A randomized clinical trial published in Biological Psychiatry studied 40 Hz transcranial alternating current stimulation in autistic children and reported improvement in social-function measures.
What evidence is available?
Early randomized trial
Regulatory or policy status
Experimental for autism
Why this matters · What it does not prove
Why this matters
A randomized trial is more informative than anecdote and adds a serious signal worth following.
Important limits and safety
One trial does not establish tACS as routine autism care. Replication, durability, safety and broader populations still matter.
ARPA-H launches SPECTRA for more precise autism research
SPECTRA will combine biological, clinical, behavioral and real-world data with advanced computational tools to study diagnosis, trajectories and individual response to support.
What evidence is available?
Government research initiative
Regulatory or policy status
No authorized diagnostic or therapy
Why this matters · What it does not prove
Why this matters
Autism is highly heterogeneous; better validated subgroups and trajectories could eventually support more individualized care.
Important limits and safety
This is a research program underway—not a new diagnostic test or treatment available today.
Phase 3 ecopipam trial adds important Tourette evidence
A 2026 JAMA Neurology phase 3 randomized clinical trial evaluated ecopipam, a selective dopamine D1 receptor antagonist, in children, adolescents and adults with Tourette syndrome.
What evidence is available?
Randomized Phase 3 withdrawal trial
Regulatory or policy status
Investigational, not FDA approved
Why this matters · What it does not prove
Why this matters
Later-stage evidence for a different dopamine mechanism expands the options researchers, clinicians and regulators can evaluate.
Important limits and safety
Research news is not prescribing advice. Current regulatory status, risks, alternatives and CBIT still belong in the clinical conversation.
Educational reporting, not a diagnosis, prescription or treatment recommendation. Statuses describe the specific indication, research and review date—not a permanent safety or effectiveness ranking. Confirm regulatory status and individual suitability with a qualified clinician.
Earlier featured research collections
NEW · OCTOBER 22, 2026 · EVIDENCE IN PERSPECTIVE
Bipolar medication, ultrasound and AI brain scans: three findings, three different levels of certainty.
New real-world research links long-acting aripiprazole to fewer hospital visits—but also greater obesity and movement-symptom risks. A ten-person ultrasound trial offers only an early psychosis signal. And a 14-study AI imaging review finds promise without reliable clinical validation. Read our sourced, evidence-graded guides.
FEATURED · OCTOBER 2026 · SCHIZOPHRENIA & METABOLIC HEALTH
One FDA-approved treatment. One important observational study. Know the difference.
WELTRUZA is a newly FDA-approved once-monthly olanzapine injection for adults with schizophrenia; metabolic and other monitoring remains essential. Separately, a peer-reviewed study of 70,257 adults with schizophrenia and type 2 diabetes linked GLP-1 therapy initiation to fewer psychiatric hospital and emergency visits. That association does not prove a psychiatric benefit or make GLP-1 drugs approved schizophrenia treatments. Read the evidence and safety limits side by side.
Brain-wave-selected autism trials and schizophrenia mRNA research: what has actually been shown?
CLARITY will test an investigational autism medicine in an EEG-defined subgroup; the subgroup analysis is a non-peer-reviewed preprint, not a clinical result. Separately, peer-reviewed GRIA3 mRNA research in neurons and mice is still preclinical. Both explainers separate promising science from available treatments.
NEW · OCTOBER 16, 2026 · GENETICS & NEUROTECHNOLOGY
36 OCD and Tourette risk genes—discovery, not a new treatment.
Read what a large genomic study shows about shared risk and why ERP and CBIT still matter. Also explore the FDA focused-ultrasound workshop and a carefully interpreted study of caffeine, sleep and developing brains.
FEATURED · OCTOBER 16, 2026 · RESEARCH WITH CONTEXT
New questions, mixed results, and no shortcuts to evidence.
A 70,257-person schizophrenia-and-diabetes study found a promising observational association with GLP-1 medicines. A Phase 3 social-anxiety drug did not beat placebo. And an August bipolar TMS case series is receiving renewed attention. Compare the evidence and limitations before the headlines.
A new treatment option is not the same as a new experimental promise.
Compare the FDA-approved WELTRUZA injection with obuprazine's new, investigational Phase 2b results, ecopipam's Tourette research and evenamide's continuing clinical hold.
Support should not begin only when the waiting ends.
The October 9 review in England argues for needs-led support alongside timely, appropriate diagnosis. Learn what was recommended, what remains uncertain and what families can explore in the United States.